|
|
Post by peppy on Mar 7, 2016 20:23:36 GMT -5
|
|
|
|
Post by qwertqwert on Mar 7, 2016 20:33:58 GMT -5
Is that guess as good as mine? sean Cunningham / Google canada Healthcare partner lead. I found his name in the receptorlife website. Hmmmmmm....... |
|
|
|
Post by peppy on Mar 7, 2016 20:37:11 GMT -5
Is that guess as good as mine? sean Cunningham / Google canada Healthcare partner lead. I found his name in the receptorlife website. Hmmmmmm....... I like your work better |
|
|
|
Post by qwertqwert on Mar 7, 2016 23:37:26 GMT -5
Is that guess as good as mine? sean Cunningham / Google canada Healthcare partner lead. I found his name in the receptorlife website. Hmmmmmm....... I like your work better This never ends. Google Canada in Toronto - area code "416". Remember the colourful image on receptorlife Twitter page? The numbers "416" was partially visible. If if not him. My second guess is Sean L. Cunningham from GTCR.com |
|
|
|
Post by peppy on Mar 14, 2016 8:31:30 GMT -5
I ran across this information while reading. It can be legally studied then. ?
United States[edit]
Cannabidiol (CBD) has received orphan drug status in the United States, for treatment of Dravet syndrome which will allow it to be studied.[56]
UK[edit]
Cannabidiol, in an oral-mucosal spray formulation combined with delta-9-tetrahydrocannabinol, is a prescription product available for relief of severe spasticity due to multiple sclerosis (where other anti-spasmodics have not been effective).[57]
GWPH
In this study, patients taking Epidiolex achieved a median reduction in monthly convulsive seizures of 39 percent compared with a reduction on placebo of 13 percent, which was highly statistically significant (p=0.01).
Dravet syndrome is a rare form of epilepsy that is difficult to treat. It is a catastrophic form of intractable epilepsy that begins in infancy. Initial seizures are most often prolonged events and in the second year of life other seizure types begin to emerge.
en.wikipedia.org/wiki/Cannabidiol
|
|
|
|
Post by sluggobear on Mar 14, 2016 9:25:34 GMT -5
I ran across this information while reading. It can be legally studied then. ?
United States[edit]
Cannabidiol (CBD) has received orphan drug status in the United States, for treatment of Dravet syndrome which will allow it to be studied.[56]
UK[edit]
Cannabidiol, in an oral-mucosal spray formulation combined with delta-9-tetrahydrocannabinol, is a prescription product available for relief of severe spasticity due to multiple sclerosis (where other anti-spasmodics have not been effective).[57]
GWPH
In this study, patients taking Epidiolex achieved a median reduction in monthly convulsive seizures of 39 percent compared with a reduction on placebo of 13 percent, which was highly statistically significant (p=0.01).
Dravet syndrome is a rare form of epilepsy that is difficult to treat. It is a catastrophic form of intractable epilepsy that begins in infancy. Initial seizures are most often prolonged events and in the second year of life other seizure types begin to emerge.
en.wikipedia.org/wiki/Cannabidiol
GW Pharma has cracked the first nut with CBD - stock was up over 100% today. It's important also because they are the first one (I think) to demonstrate controlled (read: "metered") and reproducible CBD dose concentrations. Still very much my speculation but if RLS is in this business (THC/CBD) then my primary question is: are they intending to pursue clinical trials and FDA approval for specific indications or simply provide a neutraceutical-like market with a legal (in WA) plant extract using TS for controlled, metered dosing? I hope they take the revenues first route (no claims) and then pursue clinical indications. How jaded I have become about the "science of medicine" ...because I want/need MNKD to succeed! |
|
|
|
Post by sluggobear on Mar 14, 2016 9:28:12 GMT -5
Also interesting when you look at GW Pharma (GWPH) Yahoo finance page, it looks like all of the same vulture law firms were trying to file class actions... finance.yahoo.com/q?s=GWPH&ql=1 |
|
|
|
Post by mnholdem on Mar 14, 2016 9:55:28 GMT -5
I read that first thing this morning:
GW Pharma (GWPH) Shares Double as Cannabis Drug Meets Goals in Phase III Study
LONDON, March 14, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (GWPH) (GWP.L) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of Dravet syndrome. In this study, Epidiolex achieved the primary endpoint of a significant reduction in convulsive seizures assessed over the entire treatment period compared with placebo (p=0.01). Epidiolex has both Orphan Drug Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA) in the treatment of Dravet syndrome, a rare and debilitating type of epilepsy for which there are currently no treatments approved in the U.S.
Source: www.biospace.com/News/gw-pharma-shares-double-as-cannabis-drug-meets/412133/source=TopBreaking
|
|
|
|
Post by lakers on Mar 14, 2016 15:07:17 GMT -5
GW Pharmaceuticals announced Monday that the first of its four major studies of the cannabis-based drug appeared to dramatically reduce seizures in patients with Dravet syndrome, a rare and severe form of epilepsy. “This shows that cannabinoids can produce compelling and clinical important data and represent a highly promising new class of medications, hopefully in a range of conditions,” Justin Gover, GW Pharmaceuticals’ chief executive, told Reuters. The trial, which involved 120 patients, showed that the median reduction in convulsive seizures was 39 percent in those taking the drug, called Epidiolex, versus 13 percent in those taking a placebo. The mean age of patients was 10 years old and they had previously tried and failed an average of more than four anti-epileptic treatments. GW is also conducting other Phase 3 studies on Dravet syndrome with 150 patients and Lennox-Gastaut Syndrome and Tuberous Sclerosis Complex. Desperate, the family began treating her with a few drops of an extract made from a strain of marijuana that was high in CBD, which is thought to be medicinal, and low in THC, the component that creates a high. The family reported that the seizures nearly stopped. As their story spread across the country, parents held bake sales, benefit concerts and other fundraisers to try to raise money for their own children. Hundreds moved to Colorado while others tried to work within their own states to legalize the use of the treatment. Devinsky, who has a child with epilepsy himself, was one of the early proponents of trying to do rigorous clinical trials of the drug and teamed up with GW Pharmaceuticals, which had previously been working on cannabis-derived drugs for multiple sclerosis. www.washingtonpost.com/news/to-your-health/wp/2016/03/14/cannabis-derived-drug-shows-promise-for-kids-with-epilepsy-gw-pharma-stock-doubles/ |
|
|
|
Post by 4allthemarbles on Mar 14, 2016 15:12:12 GMT -5
Wonder if that affected any other bio techs.
|
|
|
|
Post by lakers on Mar 14, 2016 15:30:14 GMT -5
Epidiolex wins regulatory approval, it would be the first prescription drug in the United States that is extracted from marijuana. The drug is a liquid containing cannabidiol 100mg/mL, a component of marijuana that does not make people high. [inhaling would be effective faster] As many as 30 percent of the nearly 500,000 American children with epilepsy are not sufficiently helped by existing drugs, according to GW. Parents of some of these children have been flocking to try marijuana extracts, prepared by medical marijuana dispensaries. Eight patients getting Epidiolex and one getting the placebo withdrew from the trial because of side effects. Major side effects included drowsiness, diarrhea, decreased appetite, fatigue, fever, vomiting and upper respiratory infection. But GW said that over all, the drug was well tolerated. GW, which is based in London, said Monday that it would meet with the Food and Drug Administration to see if Epidiolex could be approved based on this single study. It is expecting the results of another trial for Dravet syndrome later this year, and the results of two trials in another form of epilepsy, Lennox-Gastaut. There are no drugs approved specifically for Dravet syndrome, which typically starts in infancy and affects about 5,000 children in the United States, according to the company. It is not yet known if Epidiolex can help with the walking problems and intellectual disability that can come with Dravet, Dr. Devinsky said. American depositary receipts of GW were up about 130 percent in midday trading. The company, which specializes in cannabis-based pharmaceuticals, already sells Sativex to treat spasticity [another RLS' app] associated with multiple sclerosis. It is approved in many countries, though not the United States. While Epidiolex could be the first prescription drug in the United States extracted from marijuana, two drugs already on the market, dronabinol and nabilone, are synthetic chemicals either similar to or identical to delta-9 THC, the component of marijuana that produces the highs. Those drugs are approved to treat nausea and vomiting caused by cancer chemotherapy. Dronabinol is also approved to treat weight and appetite loss in patients with AIDS. mobile.nytimes.com/2016/03/15/business/marijuana-based-drug-found-to-reduce-epileptic-seizures.html?_r=0&referer=https://news.google.com/ |
|
|
|
Post by lakers on Mar 18, 2016 13:15:25 GMT -5
cgiscgis brought up a new USA trademark for both "Receptor" and "Receptor Life Sciences" "Receptor Life Sciences"ReceptorThere is a nugget (or nug, as the kids say) of information -- Though not definitive, this is support for claims that the API is some sort of cannabis extract. Piper Jaffray Backs GW Pharmaceuticals PLC- ADR (GWPH) Following a Call with Specialist Jason Cohen, Editor — March 18, 2016, 9:32 AM EDT In a research report released this morning, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on shares of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), with a price target of $147, after hosting a call with a pediatric epilepsy specialist familiar with CBD and artisanal CBD/marijuana formulations to discuss the current treatment paradigm and GW Pharma’s recent Phase 3 results in Dravet Syndrome (DS). Schimmer wrote, “Based on the data available in the press release of 39% median seizure reduction in Epidiolex treated pts vs. 13% for pbo, the specialist believes this is a robust exciting result and one that is largely in line and confirms the data from the expanded access / artisanal preparations. Though he is very familiar with all the feedback and successful anecdotal results from patients / families, his belief is the Phase 3 results actually replicate the prior open label experience when one closely analyzes the seizure journals kept by patients’ families in the expanded access program.” “Overall, in his view there remains a broad and high unmet need in both DS and Lennox Gastaut Syndrome (LGS) as well as the broader refractory epilepsy population. Based on the totality of the results so far, the specialist believes the data will ultimately support use of Epidiolex as a broad activity anti-seizure drug with a well-tolerated profile, supporting substantial use potentially on par with Onfi,” the analyst concluded. www.smarteranalyst.com/2016/03/18/piper-jaffray-backs-gw-pharmaceuticals-plc-adr-gwph-following-call-specialist/ |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Mar 18, 2016 16:14:51 GMT -5
I believe Zogenix (zgnx) also has orphan drug status for Dravet syndrome. I thought only one company could have orphan status.
|
|
|
|
Post by peppy on Mar 19, 2016 2:05:31 GMT -5
cgiscgis brought up a new USA trademark for both "Receptor" and "Receptor Life Sciences" "Receptor Life Sciences"ReceptorThere is a nugget (or nug, as the kids say) of information -- Though not definitive, this is support for claims that the API is some sort of cannabis extract. Piper Jaffray Backs GW Pharmaceuticals PLC- ADR (GWPH) Following a Call with Specialist Jason Cohen, Editor — March 18, 2016, 9:32 AM EDT In a research report released this morning, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on shares of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), with a price target of $147, after hosting a call with a pediatric epilepsy specialist familiar with CBD and artisanal CBD/artmarijuana formulations to discuss the current treatment paradigm and GW Pharma’s recent Phase 3 results in Dravet Syndrome (DS). Schimmer wrote, “Based on the data available in the press release of 39% median seizure reduction in Epidiolex treated pts vs. 13% for pbo, the specialist believes this is a robust exciting result and one that is largely in line and confirms the data from the expanded access / artisanal preparations. Though he is very familiar with all the feedback and successful anecdotal results from patients / families, his belief is the Phase 3 results actually replicate the prior open label experience when one closely analyzes the seizure journals kept by patients’ families in the expanded access program.” “Overall, in his view there remains a broad and high unmet need in both DS and Lennox Gastaut Syndrome (LGS) as well as the broader refractory epilepsy population. Based on the totality of the results so far, the specialist believes the data will ultimately support use of Epidiolex as a broad activity anti-seizure drug with a well-tolerated profile, supporting substantial use potentially on par with Onfi,” the analyst concluded. www.smarteranalyst.com/2016/03/18/piper-jaffray-backs-gw-pharmaceuticals-plc-adr-gwph-following-call-specialist/This PHD presentation: "IN animal studies, exact optimal dosage of CBD for arthritis was found to be 5mg/kg. screencast.com/t/6umatXajCPS CBD definitely blocks the inflammation with clinical score. at 5mg/kg in clinical score.", "if we give less than that we get less action, if we give more than that we get less action." www.youtube.com/watch?v=c8EdQHWhAT8 it seems optimal dosing is best.
(andrea is working at receptor?)
|
|
|
|
Post by peppy on Mar 19, 2016 3:22:56 GMT -5
Is that guess as good as mine? sean Cunningham / Google canada Healthcare partner lead. I found his name in the receptorlife website. Hmmmmmm....... I like your work better
This video complete with animal study data and clinical trials. at the end, work done in Israel, collaborators aboard include CANADA location.
screencast.com/t/4zpsWatIJ
www.youtube.com/watch?v=c8EdQHWhAT8
This probably has not escaped googles' attention. screencast.com/t/6umatXajCPS
|
|
